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tients lacking liver metastases (M0). EC-cell tumors were sig-
nificantly larger in the M1 group of tumors, while VMAT-1 
expression was significantly decreased. We found an inverse 
correlation between tumor size and prognosis. Univariate 
analysis further revealed that decreased expression of
VMAT-1, MMP-2 and TIMP-3 in primary tumors was signifi-
cantly associated with a reduced survival time of the pa-
tients.  Conclusion: Our data reveal that MMP-2 and TIMP-3 
expression together with VMAT-1 expression are of potential 
prognostic and clinical value in ileal carcinoids. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Ileal carcinoids are usually composed of serotonin-
producing enterochromaffin (EC) cells and belong to the 
well-differentiated neuroendocrine carcinomas of the 
gut. They represent the vast majority of the neuroen-
docrine tumors (NETs) of the ileum  [1] , as polypeptide 
YY-producing L-cell tumors and neurotensin-producing 
N-cell tumors are exceptionally rare  [2] . The major ther-
apeutic challenges of EC-cell carcinoids are liver metas-
tases which respond only very poorly to therapy  [3] . 
Knowledge about the events during invasion and forma-
tion of metastases of EC-cell carcinoids is very limited. 
Prognosis of ileal carcinoids and patients’ quality of life 
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 Abstract 
 Purpose: Ileal carcinoids are gut epithelial tumors originat-
ing from serotonin-containing enterochromaffin (EC) cells. 
Therapeutic options for effectively inhibiting the growth 
and spread of metastatic carcinoids are still limited. We 
aimed to identify the role of matrix metalloproteinases 
(MMPs) and their endogenous tissue inhibitors (TIMPs) dur-
ing tumor development and metastasis.  Patients and Meth-
ods: Tissue samples were obtained from surgically treated 
patients. Expression of the EC-cell marker, vesicular mono-
amine transporter-1 (VMAT-1), was used to verify ileal carci-
noids. We investigated the differential expression of MMP-2, 
7, 9, 11, and 13 and their endogenous inhibitors (TIMP-1, 2, 
and 3) by quantitative real-time RT-PCR in 25 primary tu-
mors, their corresponding lymph node metastases and/or 
liver metastases and matched normal mucosa.  Results: Sig-
nificantly increased expression of VMAT-1, MMP-2, MMP-11, 
TIMP-1 and TIMP-3 was determined by quantitative RT-PCR 
in EC-cell carcinoids compared to normal intestinal mucosa 
(p  ! 0.05). In contrast, MMP-2 and MMP-9 as well as TIMP-1, 
TIMP-2, and TIMP-3 expression in primary tumors of patients 
with liver metastases (M1) was significantly lower than in pa-
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correlate with the presence of metastases in the liver 
which depends on the size of the primary tumor. If the 
tumor is  ! 1 cm, only 20–30% metastasize into the senti-
nel lymph nodes and eventually into the liver. If the size 
exceeds 2 cm, there is a 80% probability of metastases in 
the lymph nodes and a 50% probability of metastases in 
the liver  [4, 5] . Therefore, during the course of tumor de-
velopment, there might be a step of proteolytic dysregula-
tion causing deranged ratios of proteases and their in-
hibitors which we sought to discover in the current proj-
ect.
 A family of proteases possibly involved in tumor inva-
sion are matrix metalloproteinases (MMPs), which are 
physiologically expressed at low levels in chromaffin cells 
and other neuroendocrine cells, e.g. in the thyroid  [6] . 
There are about 25 subtypes of MMPs, which are mem-
brane-bound or secreted comprising collagenases (MMP-
1, 8, 13, and 18), gelatinases (MMP-2 and 9), stromelysins 
(MMP-3, 10, and 11), matrilysins (MMP-7 and 26), and 
membrane-type MMPs (MMP-14–17, 24, and 25)  [7] . 
MMPs are involved in the physiological remodeling of 
tissues and they also play a role in tumor progression and 
metastasis  [6, 8] . Various MMPs have been shown to in-
fluence the initiation, invasion and metastasis of tumors 
 [8, 9] .
 In the human organism, there are endogenous tissue 
inhibitors of MMPs, the TIMPs. Four TIMPs, found in 
almost all tissues and body fluids, have currently been 
characterized in humans and designated TIMP-1, 2, 3, 
and 4. TIMP-1, 2, and 4 are present in soluble forms, 
while TIMP-3 is bound to the extracellular matrix (ECM). 
The expression pattern of TIMP-4 differs from that of the 
other TIMPs. TIMP-4 mRNA is localized in the brain 
and heart of adult humans, as well as the ovary and skel-
etal muscle, suggesting a role as an important tissue-spe-
cific regulator of ECM remodeling  [10] . The balanced ac-
tivities of MMPs and TIMPs are involved in normal and 
pathological events such as wound healing, tissue remod-
eling, angiogenesis, invasion, tumorigenesis and metas-
tasis. TIMPs turn out to be multifunctional proteins 
which regulate different processes through MMP-depen-
dent as well as MMP-independent pathways that might 
even be paradoxical or controversial  [11, 12] .
 Until now, only little is known about the role of MMPs 
and TIMPs in endocrine tumors. Carcinoids of the small 
intestine are a relatively rare tumor disease. This fact may 
cause a possible bias in the data achieved, thus presenting 
a limiting aspect to studies about this tumor entity. How-
ever, we have used quantitative real-time RT-PCR analy-
sis of primary EC-cell carcinoids, lymph node metastases 
and liver metastases to examine the level and pattern of 
the expression of MMPs and TIMPs exactly. We investi-
gated the association of these factors with the progression 
of EC-cell carcinoids and examined their usefulness as 
prognostic markers.
 Patients and Methods 
 Patient Characteristics and Specimens 
 This retrospective study included patients first diagnosed and 
treated between 1992 and 2004 at the Klinikum rechts der Isar, 
Technical University of Munich, Germany. Tissue samples from 
28 patients with ileal carcinoids with lymphatic and/or hepatic 
metastases were histological evaluated by 2 different histopathol-
ogists and were investigated after obtaining informed consent. To 
confirm tumor origin an evaluation of the expression of the 
marker protein for EC-cells, vesicular monoamine transporter-1 
(VMAT-1), in the primary tumor was performed. As a negative 
control, two duodenal carcinoids were evaluated but not included 
in the study and further analysis. In our study, the cutoff value 
was set at 1,000 VMAT-1 mRNA copies/10 6 GAPDH mRNA cop-
ies in the primary tumor since this level corresponded to the 
99.9% confidence interval. Three patients with ileal carcinoids 
were removed from the study because we did not find a VMAT-1 
expression level above 1,000 VMAT-1 mRNA copies/10 6 GAPDH, 
in parallel with negative staining for VMAT-1, and negative stain-
ing for chromogranin and/or serotonin. Consequently, these 3 
patients were removed from the study since the origin of those 
tumors could not be determined accurately as ileal EC-cell carci-
noids. Thus, the work compares a homogenous group of 25 pa-
tients with ileal EC-cell carcinoids.
 The included patients with primary tumors of ileal carcinoids 
were surgical treated, all of them showed lymphatic infiltration 
(n = 25 lymph node positive). 10 patients had liver metastases, but 
liver tissue samples were only obtained in 8 patients by biopsy or 
during surgical removal (n = 10, liver positive). All tumors were 
found to be well-differentiated according to the histological re-
ports. 15 patients were female and 10 male. The average age at first 
diagnosis and surgery was 59  8 14 (range 35–87) years. Further 
characteristics, e.g. additional therapy, TNM status, grading, etc., 
of the patients included in the study are summarized in  table 1 . 
TNM staging was performed following current guidelines for en-
docrine ileal tumors  [13] . T1 was defined as tumors invading the 
mucosa or submucosa with diameters of  ^  1 cm. T2 was defined 
as tumors invading the muscularis propria or showing diameters 
of  1 1 cm; T3 = tumors invading the subserosa, and T4 = tumors 
invading the peritoneum and/or other organs; m = multiple tu-
mors. As all patients presented lymph node metastases at the time 
of diagnosis, disease stage was at least IIIB for any T, N1, and M0 
or stage IV for any T and any N or M1. Ki-67 staining was per-
formed, positive cells were counted, and corresponding grading 
stages are listed in  table 1 . Grading distinguishes between three 
grades: G1 = Ki-67 index  ^  2%; G2 = Ki-67 index between  1 2 and 
20%, and G3 = Ki-67 index  1 20%. Most tumors had a Ki-67 index 
of  ! 2% and were thus well-differentiated. Three patients were lost 
during follow-up and defined as dropouts. Complete follow-up 
was available for 22 patients, of whom 8 died and 14 were still alive 
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at the defined evaluation time point, April 1, 2007. Three of the 
22 patients had to be classified as dropouts at 1 month (disease 
unrelated death), 26 and 28 months (last secure proof of life). 
None of the patients received additional medical treatment such 
as somatostatin analogs or chemotherapy before surgery, thus ex-
cluding an effect of additional treatment on the expression pat-
terns.
 Tissue Preparation 
 Under RNAse-free conditions, formalin-fixed paraffin-em-
bedded tissue samples were sectioned at 10   m, mounted on 
 Super-Frost  Plus glass slides (Menzel GmbH & Co. KG, Braun-
schweig, Germany) and processed without delay. Slides were de-
waxed in two changes of xylene, rehydrated and stained with he-
matoxylin-eosin (HE) if necessary. Whole tissue or separated ar-
eas (tumor or normal mucosa) of the section was scraped off to 
extract total RNA. Because carcinoids are typically represented 
by densely packed tumor cells with a very small stromal part, it 
was possible to dissect the tumor tissue of each section from the 
normal mucosa. Tissue amounts per slide depended on tumor or 
tissue section size and lay between 300 and 50 mm 2 in most cases. 
In 5 liver metastases where biopsies were taken, tissue amounts 
had a size of 25 mm 2 . Small amounts were balanced by the num-
ber of serial tissue sections used.
 RNA Extraction and cDNA Synthesis by RT-PCR 
 Scraped-off tissue was immersed in 200   l lysis buffer (Tris/
HCl,; pH 8.0; 0.1 mmol/l EDTA, pH 8.0; 2% SDS, pH 7.3) and 500 
  g proteinase K (Applichem, Darmstadt, Germany) and incubat-
ed for 16 h at 60 ° C until completely lysed. RNA was extracted by 
a classical phenol/chloroform method and precipitated with an 
equal volume of isopropanol, 0.1 vol of 3 mol/l sodium acetate and 
20   g carrier glycogen (Roche, Mannheim, Germany) at –20  ° C 
for a minimum of 2 h. Subsequently, the RNA pellet was washed 
once in 70% ethanol, dried and resuspended in 20   l of RNAse-
free water. The RNA was transcribed into cDNA using Super-
script II Reverse Transcriptase (Invitrogen, Karlsruhe, Germany), 
according to manufacturer’s instructions.
Table 1. Patient characteristics
Patient
No.
Therapy after surgery Tumor stage LN Liv. met. Disease 
stage
Grading Tumor size
Ø mmCtx Rtx Dot Som Inf pT1 pT2 pT3 pT4 m N1 M0 M1 G1 G2
n = 25 3 0 2 7 3 3 10 6 6 7 25 15 10 19 6 mean 19811
1 x x x IV x 30
2 x x x x x IV x 30
3 x x x x IIIB x 30
4 x x x IV x 25
5 x x x x x x IV x 50
6 x x x IIIB x 4
7 x x x x IIIB x 10
8 x x x x IV x 15
9 x x x x IIIB x 15
10 x x x IV x 22
11 x x x x x x IV x 30
12 x x x x x x x IV x 15
13 x x x x IIIB x 12
14 x x x x IIIB x 12
15 x x x IIIB x 15
16 x x x IIIB x 8
17 x x x IV x 15
18 x x x x IIIB x 15
19 x x x IIIB x 10
20 x x x IIIB x 13
21 x x x IIIB x 25
22 x x x IIIB x 20
23 x x x IIIB x 3
24 x x x IIIB x 15
25 x x x x x x IV x 30
Additional therapies following surgery included chemotherapy (Ctx), radiation (Rtx), Dotatoc (Dot), Somatostatin analogs (Som), 
and interferon (Inf). The table describes tumor stage according to the TNM status, disease stage, grading according to Ki-67 index, 
and tumor size. m = Multiple tumors; LN = lymph node; Liv. met. = liver metastasis.
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 Quantitative RT-PCR 
 Quantitative TaqMan  real-time RT-PCR was performed us-
ing the ABI PRISM 7700 sequence detection system (Applied Bio-
systems, Foster City, Calif.) as described previously  [14, 15] . To 
equalize for different tissue amounts, mRNA copy numbers of all 
genes investigated were normalized to 10 6 GAPDH mRNA copies 
obtained for each tissue sample. Using the constant expression 
level of the housekeeping gene GAPDH in human cells for nor-
malization gives the relative copy numbers for each investigated 
gene. Primer and probe sequences are listed in  table 2 . PCR prod-
uct lengths were 66–84 bp.  Table 3 gives an overview of all results 
obtained by quantitative RT-PCR. To avoid potential problems 
caused by the use of formalin-fixed paraffin-embedded tissue we 
used a classical phenol/chloroform extraction followed by RNA 
precipitation that allows recovery of short RNA fragments.
 Immunohistochemistry 
 For VMAT-1 staining, after deparaffinization of the tissue sec-
tions (4   m) of interest, endogenous peroxidase activity was 
quenched by pretreatment with 0.7% methanol and 6.4% H 2 O 2 in 
0.01  M phosphate-buffered saline (PBS; pH 7.4) for 20 min. Next, 
tissue was unmasked by heating in the microwave oven for 15 min 
at 800 W and 15 min at 400 W in 10 m M citric acid (pH 6.0), fol-
lowed by incubation with 5% normal goat serum for 30 min and 
with a rabbit anti-human VMAT-1 antibody (Biotrend, Cologne, 
Germany) diluted 1: 250 in 5% normal goat serum overnight at 4 ° C. 
After further incubation with a biotinylated goat anti-rabbit anti-
body (Dianova, Hamburg, Germany) diluted 1: 500 in 5% normal 
goat serum for 2 h and with an ABC kit (Vector, Burlingame, Calif.) 
for 2 h, immunoreaction was visualized by treatment with 0.09% 
diaminobenzidine and 0.03% H 2 O 2 in 0.05  M Tris-HCl (pH 7.6). 
For MIB-1 staining and Ki-67 index, the immunohistochemical 
staining was performed on an automated staining system (Ventana 
BenchMark, Ventana Medical Systems, Tucson, Ariz.). Antigen re-
trieval was performed by heating (CC1 mild, Ventana BenchMark). 
The primary antibody, a monoclonal mouse anti-human anti-Ki-
67-antigene for clone MIB-1 (Dako ChemMate, Glostrup, Den-
mark), was incubated for 20 min at a dilution of 1: 100. Visualiza-
Table 2. Sequences of primer and probes for quantitative RT-PCR analysis
Gene Forward primer Reverse primer Fluorogenic probe
GAPDH 5-GGGAAGCTTGTCATCAATGGA-3 5-CGCCCCACTTGATTTTGG-3 5-ATCCCATCACCATCTTCCAGGAGCG-3
VMAT-1 5-TTCCTGGCACTACTGGATGGA-3 5-GAGTCCCCTTGGCACTCTCA-3 5-CACTCCAGCTTTGCATCCTACAGCCTTC-3
MMP-2 5-CGATGTCGCCCCCAAA-3 5-GGGCAGCCATAGAAGGTGTTC-3 5-CGGACAAAGAGTTGGCAGTGCAATACC-3
MMP-7 5-CGGGAGGCATGAGTGAGCTA-3 5-GCATTTTTTGTTTCTGAGTCATAGAGA-3 5-AGTGGGAACAGGCTCAGGACTATCTCAAGAG-3
MMP-9 5-CAGACATCGTCATCCAGTTTGG-3 5-CCGTCCTTCCCGTCGAA-3 5-CGCGGAGCACGGAGACGGGTAT-3
MMP-11 5-CTGGGATAGACACCAATGAGATTG-3' 5-TGGAGACCGCGTCAAAGG-3 5-TGGAGCCAGACGCCCCGC-3
MMP-13 5-GATGAAGATGATTTGTCTGAGGAAGA-3 5-CGCGAGATTTGTAGGATGGTAGT-3 5-CTCCAGTTTGCAGAGCGCTACCTGAGA-3
TIMP-1 5-GCAGCGAGGAGTTTCTCATTG-3 5-GCCACGAAACTGCAGGTAGTG-3 5-TGGAAAACTGCAGGATGGACTCTTGCAC-3
TIMP-2 5-GCGTTTTGCAATGCAGATGT-3 5-CGTTTCCAGAGTCCACTTCCTT-3 5-TGATCAGGGCCAAAGCGGTCAGTG-3
TIMP-3 5-GCTGGAGGTCAACAAGTACCAGTA-3 5-GCACAGCCCCGTGTACATCT-3 5-CTGCTGACAGGTCGCGTCTATGATGG-3
Table 3. Summary of expression levels and significant differences of all investigated factors
RT-PCR
for the
following
Normal
mucosa
(n = 25)
Primary tumor
(n = 25)
LN metastases
(n = 24 )
Liver
metastases
(n = 8)
Primary tumor
vs. normal
mucosa, p value
LN metastases
vs. normal
mucosa, p value
Liver metastases 
vs. normal 
mucosa, p value
MMP-2 122,410821,854 161,016847,932 46,460810,165 8,25583,864 n.s. 0.002a 0.003a
MMP-7 381 483 281 37815 n.s. n.s. n.s.
MMP-9 6908196 9658263 9,30283,624 2208191 n.s. 0.051 n.s.
MMP-11 1,7298474 4,0328789 5,46381,251 4,99582,062 0.005 n.s. n.s.
MMP-13 2088108 96830 142866 77831 n.s. n.s. n.s.
TIMP-1 2,1238472 20,05585,777 14,45783,163 10,09584,387 <0.001 <0.001 0.038
TIMP-2 148,494822,216 302,094864,847 276,383893,451 54,25185,004 n.s. n.s. n.s.
TIMP-3 31,256811,075 87,007826,340 138,513847,109 29,10789,940 0.002 0.005 n.s.
VMAT-1 4578204 222,288877,008 126,88783,3810 31,016812,574 <0.001 <0.001 <0.001
Expression levels of MMPs and TIMPs in normal mucosa, primary ileal carcinoids, lymph node (LN) metastases and liver metas-
tases determined by quantitative RT-PCR. The table summarizes the results for all investigated factors and the significant expression 
differences found between cancer tissue and normal tissue. mRNA amounts were determined by quantitative RT-PCR and are pre-
sented as relative expression normalized to 106 GAPDH mRNA copies. Values are means 8 SE.
a Downregulated.
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tion was performed using the avidin-biotin complex method, 
which yielded a brown staining signal. The immunostainings for 
MIB1 were evaluated by counting all positive and negative tumor 
cell nuclei in a punch (1,500–2,000 tumor cells) and the staining 
index was indicated as the percentage of positive cells.
 Statistical Analysis 
 Results are expressed as mean  8 SE. Data were analyzed by 
Mann-Whitney rank sum test, Kaplan-Meier survival analysis, 
and log-rank test for survival analysis, depending on the data set 
of concern. The cutoff between high and low expression of a pa-
rameter was defined as the middle value between the means of the 
M0 group and the M1 group. Values of p  ^  0.05 were considered 
to be significant.
 Results 
 VMAT-1 Expression in Ileal Carcinoids 
 VMAT-1 has previously been shown to be expressed 
predominantly in ileal carcinoids  [16] ; however, it is not 
expressed in all NETs. We therefore determined the pres-
ence of VMAT-1 in ileal carcinoids by semiquantitative 
RT-PCR and immunohistochemistry. Expression of the 
VMAT-1 was determined in 25 patients originally diag-
nosed with ileal carcinoids. In these 25 patients, VMAT-1 
expression was evaluated in normal mucosa, primary tu-
mors, lymph nodes and liver metastases by quantitative 
real-time RT-PCR, and the results are shown in  table 4 .
 To determine VMAT-1 expression and distribution on 
the protein level in our patient population, we performed 
immunohistochemistry on sections of normal mucosa, 
primary tumor, lymph node and liver metastases. As 
shown in  figure 1 for one representative patient, staining 
revealed single VMAT-1-positive EC cells distributed in 
the crypts of healthy ileal mucosa ( fig. 1 A). The compact 
primary tumors showed strong staining for VMAT-1 while 
the adjacent (non-tumor) mucosa showed only single pos-
itive EC cells ( fig. 1 B) confirming our findings obtained 
with quantitative RT-PCR analysis. The same was found 
in the lymph node metastasis ( fig. 1 C) and the liver metas-
tasis ( fig. 1 D). The intensity of staining appeared to cor-
relate with the expression levels of VMAT-1 since patients 
with strong VMAT-1 expression on RT-PCR levels also 
showed intense protein staining ( fig. 1 ). However, semi-
quantitative evaluation of VMAT-1 staining with survival 
analysis was not performed due to the strong expression.
 Tumor Size and VMAT-1 Expression Correlate with 
M0 and M1 Status 
 We next investigated the correlation between the size 
of the primary tumor and M0/M1 status of the patients. 
We found that NETs which had already metastasized into 
the liver were significantly larger (Ø 26.2  8 3.3 mm) than 
tumors in patients with no liver metastases (Ø 13.8  8 1.8 
mm;  fig. 2 A). Surprisingly, expression levels of VMAT-1 
in primary tumors inversely correlated with the M0/M1 
status ( fig. 2 B) and tumor size ( fig. 2 C). These data re-
vealed that more malignant and advanced carcinoids 
show a larger tumor mass but simultaneously produce 
significantly less VMAT-1, indicating that tumor pro-
gression of NETs is accompanied by a loss of differenti-
ated EC-cell function.
 The Ki-67 index and the subsequent grading did not 
reveal any correlation with survival or the expression of 
the MMPs or TIMPs, neither as a continuous variable nor 
when divided into grades (data not shown).
 Expression of MMPs and TIMPs in Carcinoids 
 The expression of MMPs and TIMPs was quantitative-
ly determined in healthy mucosa, primary tumor and 
Table 4. Expression of VMAT-1 in primary tumors and matched 
normal mucosa of all patients diagnosed with EC carcinoids
Patient No. Normal mucosa Primary tumor
1 0 9,500
2 106 8,190
3 93 1,208
4 88 10,796
5 128 8,610
6 313 117,480
7 280 15,332
8 45 1,044
9 0 24,652
10 334 1,091
11 12 8,892
12 63 142,877
13 4,086 83,749
14 73 187,562
15 499 1,022,278
16 55 232,577
17 108 98,756
18 271 369,121
19 230 159,330
20 84 1,731,606
21 357 174,505
22 188 394,825
23 3,550 457,174
24 162 71,802
25 311 214,885
mRNA amounts were determined by quantitative RT-PCR 
and are presented as relative expression normalized to 106
GAPDH mRNA copies. Values are means 8 SE.
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lymph node metastases matched for every patient. The 
specific MMPs and TIMPs were selected because of previ-
ous reports showing their differential expression and the 
prognostic impact of some of them in several solid tumors 
 [17] . MMP-11 expression was found to be significantly in-
creased in the tumor and even further elevated in lymph 
node metastases when compared to normal mucosa 
( fig. 3 C). In contrast, MMP-2 expression was only slightly 
increased in tumor tissue and significantly decreased in 
the lymph nodes ( fig. 3 A), while MMP-9 was significant-
ly increased only in lymph nodes ( fig. 3 B). MMP-7 and 
MMP-13 were not expressed at relevant levels and showed 
no notable differences in tumor tissues ( table 3 ).
 When analyzing the expression patterns of TIMPs, 
TIMP-1 and TIMP-3 were expressed significantly higher, 
both in the tumor and lymph node metastases compared 
to matched normal mucosa samples ( fig. 3 D, F). TIMP-2 
also showed an increased expression in tumor tissue but 
this was not statistically significant ( fig. 3 E).
 Table 3 summarizes the results for all investigated fac-
tors and significant expression differences detected. 
When comparing the expression levels of MMPs and 
TIMPs in liver metastases (n = 9) with normal mucosa 
samples, MMP-2 expression was significant decreased 
and TIMP-1 expression significant increased ( table 3 ). 
Immunohistochemical staining for MMPs and TIMPs 
could not be established.
NET primary tumor 
100×
Lymph node metastasis Liver metastasis
100×
Normal mucosa
100×
400×
100×
A
B C D
 Fig. 1. VMAT-1 protein expression in neuroendocrine tumors and 
normal intestinal mucosa. Immunohistochemistry of tissue sec-
tions of one representative patient.  A Staining with anti-VMAT-1 
showed single positive EC cells distributed in the healthy ileal 
mucosa.  B In the primary tumor a strong staining for VMAT-1 
was found with the adjacent non-tumorous mucosa showing the 
typical diffuse distribution of single positive EC cells (arrows).
 C Lymph node staining revealed a strong positivity for VMAT-1 
in the area of the tumor metastasis while adjacent healthy lymph 
node tissue was negative.  D A similar picture was found in the 
liver metastasis with the tumor tissue being positive for VMAT-1 
and the healthy liver tissue remaining negative. 
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 Correlation of MMP and TIMP Expression in 
Primary EC-Cell Tumors with M0/M1 Status 
 The prognosis of mid-gut carcinoids largely depends 
on the presence of metastases in the liver  [4] . Therefore, 
we analyzed the expression patterns of MMPs and TIMPs 
in the primary tumors in correlation with the M0/M1 
status of the patients. As depicted in  figure 4 , this re-
vealed a significant downregulation of MMP-2 ( fig. 4 A, 
p = 0.001) and MMP-9 ( fig. 4 B, p = 0.021) expression and 
also a decreased MMP-11 expression in tumors with liver 
metastases ( fig. 4 C) compared to tumors of M0 status. 
When investigating the inhibitors of MMPs, we found 
that also the expression of TIMP-1, 2, and 3 was decreased 
in the primary tumors of patients with M1 status ( fig. 4 D–
F). This reduction in expression was even more pro-
nounced and highly significant for all three TIMPs.
 Prognostic Relevance of MMP and TIMP Expression 
in Patients with NETs 
 The most important question of this retrospective 
study finally was to determine whether prognostic fac-
tors for the survival of patients with ileal carcinoids can 
be defined. Survival analysis revealed a relationship be-
tween low expression of various factors and survival time 
after resection of the carcinoid independent of additive 
therapy. Decreased expression levels of MMP-2 ( fig. 5 B, 
p = 0.017) and TIMP-3 ( fig. 5 D, p = 0.02) in the primary 
tumor correlated significantly with an unfavorable out-
come of the disease. Also lower expression levels of 
VMAT-1 ( fig. 5 A) and TIMP-1 ( fig. 5 C) were indicative of 
poorer survival, but did not reach statistical significance, 
probably due to the relatively small patient population. 
As shown by the Kaplan-Meier plots in  figure 5 , patients 
with low expression levels of these factors in the primary 
tumor had a significantly shorter survival time than pa-
tients with high expression levels. In addition, our patient 
group exhibited the expected significant (p = 0.015) as-
sociation between survival time and status of liver metas-
tases (M0/M1; data not shown).
 Discussion 
 The current study aimed to identify factors associated 
with metastatic progression of ileal carcinoids. We inves-
tigated tumor size, stage of metastasis, grading by the Ki-
67 index and the expression of VMAT-1, a marker for EC 
cells  [16] , in 25 patients with ileal carcinoids, i.e. tumors 
originating from ileal EC cells, and correlated these pa-
rameters with each other and with survival. VMAT-1 lev-
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 Fig. 2. Correlation of tumor size, VMAT-1 expression and status 
of liver metastasis. Patients without liver metastases (M0) are 
compared to patients with liver metastases (M1) regarding maxi-
mal primary tumor diameters in mm ( A ) and VMAT-1 expression 
in the tumor ( B ).  C VMAT-1 expression levels in primary tumors 
sized  ! 20 mm maximal diameter are compared to expression lev-
els in tumors sized  6 20 mm. Expression was determined by 
quantitative RT-PCR and is shown as relative expression normal-
ized to 10 6 GAPDH mRNA copies. Values are means  8 SE. 
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els were decreased in patients with liver metastases; 
VMAT-1 expression was inversely correlated with tumor 
size. We also observed a poor prognosis in patients with 
low VMAT-1 expression levels in the primary tumor. 
These observations support the hypothesis that tumors 
become more aggressive when the differentiated neuro-
endocrine phenotype is lost.
 VMAT-1 is a transporter enabling the facilitated trans-
port of serotonin into cytoplasmatic vesicles  [18] . While 
gastric EC-like (ECL) cells express VMAT-2 responsible 
for the transport of histamine  [19] , VMAT-1 is present in 
EC cells producing serotonin  [16] . Adrenal chromaffin 
cells express both transporters  [20] . It has been shown 
that gastric ECL cell tumors can also be stained with an-
tibodies against VMAT-2, and ileal carcinoids stain pos-
itive from VMAT-1  [16] . These proteins can therefore be 
used to differentiate different tumor entities. We were 
able to confirm the EC-cell origin of ileal carcinoids in 
contrast to two duodenal ECL cell carcinoids by VMAT-1 
mRNA expression levels and immunohistochemical 
staining. VMAT-1 expression has also been detected in 
pheochromocytoma cells  [21] , however, contamination 
with these cells can be excluded.
 In the study presented here, we were able to determine 
VMAT-1 expression in 25 patients with ileal EC-cell car-
cinoids. The strong expression proof that these 25 pa-
tients had ileal EC-cell carcinoids. It has to be mentioned 
that some tumors may be missed since not all ileal carci-
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noids express this protein; however, in order to clearly 
determine the nature of the underlying cell type, tumors 
of potentially other origin were not further evaluated to 
guarantee a homogenous group of tumors was being 
compared with regard to their expression of MMP and 
their endogenous inhibitors.
 Serotonin is an established marker for EC-cell carci-
noids. But only about 85% of jejunoileal carcinoids have 
been shown to be positive for serotonin  [22] . Consistent 
with this study, we found that 2 of the 25 tumors with a 
significant VMAT-1 expression were immunohistochem-
ically negative for serotonin. These findings suggest a 
complementary role of VMAT-1 and serotonin as diag-
nostic tools in EC-cell tumors.
 Our current study also investigated the role of expres-
sion patterns of several MMPs in mediating infiltration 
and metastasis of human ileal NETs. Only a few studies 
determined expression of MMPs and their endogenous 
inhibitors in digestive or pulmonary endocrine tumors 
by using immunohistochemistry  [23, 24] , but no infor-
mation exists whether they are expressed in mid-gut car-
cinoids, and there is no study so far comparing expres-
sion levels with survival. MMP-2 has been previously re-
ported to be a key protease for tissue destruction in the 
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gastrointestinal tract, thereby allowing tumor infiltra-
tion  [25, 26] . In our study, MMP-2 was highly expressed 
in primary NETs, suggesting a role for local tissue de-
struction and infiltration. When comparing the expres-
sion levels in the primary tumors of the patients with and 
without liver metastases, we found that patients with low 
expression levels had more frequent liver metastasis and 
a shorter survival time. The expression level of MMP-2 
predicted survival and was a negative prognostic param-
eter in neuroendocrine carcinoids. These findings, how-
ever, are in contrast to observations made in many other 
gastrointestinal tumors and may be explained by the dif-
ferent cell phenotype. Increased levels of MMP-2 detect-
ed by immunohistochemistry, zymography, and RT-PCR 
have been found in gastric cancer  [27] , also correlating 
with a poor prognosis  [28, 29] . Other studies have report-
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ed increased MMP-2 expression in papillary thyroid car-
cinoma (immunohistochemistry)  [30] and pancreatic 
cancer (Northern blot)  [31] and a poor prognostic   signif-
icance of increased MMP-2 expression in carcinomas of 
the kidney (immunohistochemistry)  [32] , the colon 
(Northern blot)  [33] , breast (immunohistochemistry) 
 [34] and ovarian tumors (zymography)  [35] .
 MMP-7 was not expressed at detectable levels and was 
therefore not a prognostic parameter in NETs of the ile-
um. MMP-7 is predominantly produced by epithelial 
cells  [36] . In other cancer types, it has been shown that 
expression of MMP-7 correlates with the malignant po-
tential of various gastrointestinal tumors and patient sur-
vival, for example in gastric cancer. Our data suggest that 
MMP-7 does not influence EC-cell tumor progression by 
regulating invasion and angiogenesis. Similarly, MMP-9 
and MMP-11 were not of importance for predicting pa-
tient survival in ileal carcinoids.
 MMP-9 and MMP-11 expression levels increased sig-
nificantly with local tumor infiltration or lymph node 
metastasis, but were not prognostic markers regarding 
the overall survival or of the subgroup of patients with or 
without hepatic metastases. Increased MMP-9 expres-
sion has been found, e.g. in gastric cancer  [25, 27] , and 
inversely correlated with a prognostic significance in sev-
eral different carcinomas, for example of the breast  [34] , 
ovary  [35] , kidney  [32] , and colon  [33] . In pancreatic can-
cer, patients with MMP-11-positive carcinomas had a sig-
nificantly shorter overall survival time than did those  
 with MMP-11-negative carcinomas  [37] . In our studies, 
we did not find these parameters to be important, outlin-
ing the observation that MMPs play a diverging role in 
intestinal adenocarcinoma and ileal carcinoids.
 Of great importance, our study revealed that especial-
ly the expression patterns of the investigated TIMPs in 
invasive ileal carcinoids were of clinicopathological and 
prognostic value. While TIMP-1, 2 and 3 expression in-
creased in tumor tissue and in part also in local lymph 
nodes (TIMP-3), we found that only reduced expression 
of TIMP-3 in the primary tumor indicated a poor prog-
nosis. The correlation of TIMP-1–2 expression with sur-
vival showed divergent curves, but did not reach a statis-
tically significant difference. In other studies, increased 
expression of MMP-2, TIMP-1 and 2 has been shown to 
correlate with a poor prognosis in renal cell carcinoma 
 [32] . An inverse correlation was observed between TIMP-
2 and TIMP-3 expression levels and tumor grade in hu-
man pituitary tumors  [38] .
 In metastasizing ileal carcinoids, we found that NETs 
with reduced TIMP-3 expression in the primary tumor 
had a very unfavorable impact on disease-free survival. 
In this regard, ileal carcinoids may share similarities with 
breast cancer cells because reduced expression of TIMP-3 
within breast cancer cells was found to correlate with an 
aggressive tumor phenotype, negatively affecting the dis-
ease-free survival of both subgroups of lymph node-pos-
itive and mutant p53-negative patients  [39] . Similar find-
ings were reported in esophageal cancer where survival 
rates of patients with TIMP-3-negative cancer were sig-
nificantly lower than those of TIMP-3-positive patients, 
and the mean 5-year survival rates of patients with TIMP-
3+, +/–, and – were 50, 58, and 21%, respectively  [40] . 
Similar to our current results, the mean survival time of 
patients in that study was halved from 49 to 24 months in 
patients with reduced tumor TIMP-3 expression. These 
studies demonstrating the association between methyla-
tion of the TIMP-3 gene and esophageal cancer suggested 
that reduced differentiation might lead to methylation of 
the TIMP-3 gene resulting in reduced expression  [41] . 
These findings are in close analogy with our current data 
in NETs.
 The reasons for this inverse correlation may be as fol-
lows: TIMP-3 has also been described as a differentiation 
marker  [42] , whose biological activity is complex.  timp-
3 –/–  mice show a strong increase in liver and kidney me-
tastasis induced by EL-4 lymphoma or B16F10 melanoma 
cells, underlining that TIMP-3 inhibits metastatic dis-
semination of diverse cancer cells  [43] . Besides being an 
inhibitor for MMP-2, TIMP-3 acts as an inducer of apop-
tosis  [42] . Thus, when expression levels of TIMP-3 in the 
ECM are decreased, cell proliferation and metastasis may 
be increased. Finally, TIMP-3 has been shown to be an 
inhibitor of angiogenesis via binding to the VEGFR-2  [44, 
45] . Thus, increased vascularization of neuroendocrine 
metastases might occur when TIMP-3 expression is low-
ered. Strong vascularization is a typical feature of metas-
tasizing ileal carcinoids  [4, 46] . Previous findings in mid-
gut carcinoids using immunohistochemistry reported 
high VEGF-A levels  [47] , and VEGF-A expression pre-
dicted a poor outcome among well-differentiated NETs 
 [48] . These data indicate that angiogenesis may be a key 
factor during neuroendocrine cell growth and metasta-
sis. Further studies are currently being performed to clar-
ify this issue.
 It has to be emphasized that the current study evalu-
ated the expression patterns of MMP/TIMPs in a small 
group of 25 patients which may limit the overall value of 
the results presented here, especially with regard to the 
complex picture of MMP/TIMP interaction. However, we 
believe that the significant differences observed here 
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